Red light therapy for neuropathy draws interest for one specific reason: the standard treatment path stops at the pain signal. If you live with burning feet, numb fingertips, or the electric jolts that wake you at two in the morning, whether the cause is diabetes, chemotherapy, or nerve injury, you have probably been offered gabapentin, pregabalin, or duloxetine. Those drugs manage how the damage feels, not the damage itself.
Over 20 million Americans live with peripheral neuropathy (National Institute of Neurological Disorders and Stroke), and among people with diabetes, roughly half will develop some form of it over their lifetime (Feldman et al., 2019, New England Journal of Medicine). Red light therapy, also called photobiomodulation, takes a different route. It uses specific wavelengths of light to reach tissue and stimulate repair inside the cell, aiming at the nerve itself rather than at the sensation the nerve is producing.
That approach now carries institutional weight. A 2025 evidence-based consensus in the Journal of the American Academy of Dermatology (Maghfour et al.) assembled a 21-expert international panel. The panel included researchers from Massachusetts General Hospital's Wellman Center, Henry Ford Health, and the Uniformed Services University of the Health Sciences. After reviewing the published research through a structured expert process, the panel reached unanimous agreement: photobiomodulation is an effective treatment option for peripheral neuropathy.
Below that consensus sits a clinical evidence base that includes placebo-controlled trials, large-scale analyses pooling thousands of patients, and objective electrical measurements of nerve function.
Key Takeaways
- A 21-expert international panel concluded photobiomodulation is effective for peripheral neuropathy. The 2025 consensus in the Journal of the American Academy of Dermatology (Maghfour et al.) reached unanimous agreement after reviewing the published research through a structured expert process. This is the strongest institutional endorsement of photobiomodulation for neuropathy published to date.
- In the largest placebo-controlled neuropathy trial of its kind, treated patients improved 52.6% while the placebo group did not change at all. A University of Minnesota trial (Argenta et al., 2017) assigned 70 patients with chemotherapy-induced neuropathy at random to light therapy or a placebo device, three sessions weekly for six weeks. Neuropathy scores fell 52.6% at eight weeks against 0% in the placebo group, with the difference too large at every measurement point to be explained by chance. Nearly 90% of treated patients reached meaningful improvement.
- Red and near-infrared light act on seven distinct biological processes in nerve tissue, from restoring cellular energy production to rebuilding the protective sheath around nerve fibers. Human trials have measured improvement in symptoms, sensation, and the electrical speed of nerve signals; the direct tissue-level evidence of nerve regrowth currently comes from laboratory and animal research, with human structural confirmation still to come.
What Neuropathy Is and Why Current Treatments Fall Short
Peripheral neuropathy is nerve damage, most often in the hands and feet. When peripheral nerves are damaged, they stop carrying signals cleanly between the brain and the body's edges. The result: burning pain, numbness, pins and needles, weak grip, unsteady balance, and in advanced cases a near-total loss of protective feeling that raises the risk of falls and wounds that will not close.
Diabetes is the leading cause. Persistently high blood sugar damages nerve fibers through multiple routes at once, and roughly half of people with diabetes develop neuropathy over their lifetime (Feldman et al., 2019). Chemotherapy is the other major driver: the drugs that kill cancer cells also injure peripheral nerves, sometimes permanently. Other causes include autoimmune disease, compression injuries such as carpal tunnel syndrome, vitamin deficiencies, and infections.
The pharmaceutical approach is, by design, symptom management. Gabapentin, pregabalin, duloxetine and opioids all change how the pain signal travels. None of them repairs the nerve. A 2025 comprehensive review in Frontiers in Photonics (Martins et al.) put the clinical picture directly: first-line neuropathy drugs, including certain antidepressants and anti-seizure medications, often deliver only partial pain relief. Many patients report less than 50% improvement, and the drugs frequently arrive with sedation, dizziness, mental fog, and digestive upset.
That leaves a real clinical question. Is there anything that stimulates the nerve to repair itself? A growing body of research suggests there is, and the institutional recognition has arrived with it.
Neuropathy medication has a clear role in acute pain management, and for many patients it remains part of the plan. What makes photobiomodulation compelling is that it operates on the biology of the nerve itself. Instead of blocking a pain signal, you are restoring the cellular energy production, growth factor signaling, and blood supply that damaged nerves need to repair. The clinical data across multiple neuropathy types now supports that mechanism. What has changed in the past two years is the level of institutional recognition: a 21-expert panel in JAAD calling it effective, position papers from the World Association for Photobiomodulation Therapy, and meta-analyses with effect sizes that match or exceed the pharmaceutical options. For patients whose current treatment stops at medication, this is worth discussing with their physician.— William Carter, MD
How Red Light Therapy Works on Damaged Nerves: Seven Biological Mechanisms
Red light therapy uses wavelengths in the red and near-infrared range, roughly 630 to 1000 nanometers, to reach into tissue and interact with structures inside the cell. The mechanisms are well documented across peer-reviewed research. In nerve tissue specifically, seven processes drive the effect.
One principle governs all of them. Photobiomodulation follows what researchers call a biphasic dose response: low to moderate amounts of light stimulate cellular activity and repair, while excessive amounts can suppress it. This is among the most consistently reproduced findings in the field (Huang et al., 2009, Dose-Response), and it has a practical consequence. Steady daily treatment at sensible settings beats occasional blasts of intensity.
Throughout this article, each study is labeled by its evidence type. The strongest evidence comes from meta-analyses, which combine results from many studies, and randomized controlled trials, where patients are assigned by chance to real treatment or a placebo. Animal and cell studies show what happens in the laboratory but have not been confirmed in people.
1. Restoring Cellular Energy Production
Damaged nerve cells are running on empty. Neurons are among the hungriest cells in the body; they need an enormous and constant supply of cellular fuel simply to function, and far more than that to repair themselves. Damage undercuts their ability to make it.
Red and near-infrared light is absorbed by an enzyme inside the cell's energy-producing machinery, at a critical step in the chain that generates cellular fuel. When light is absorbed there, the chain speeds up and energy production rises.
Wong-Riley et al. (2005) showed this directly in nerve cells, in a landmark paper in the Journal of Biological Chemistry. Light at 670 and 830 nanometers restored both the enzyme's activity and energy production in neurons whose power systems had been shut down by toxins. The wavelengths that worked best matched the exact light-absorption profile of that enzyme, which confirmed it as the target. Evidence tier: laboratory study in isolated nerve cells.
The effect has since been measured in living people. Using a specialized MRI technique that tracks energy production inside tissue, Fear et al. (2023) recorded a significant increase in the rate of energy production in the brains of older adults after a single session of 670-nanometer light therapy. This was the first time the effect had been measured directly in humans. Evidence tier: human study, healthy volunteers.
This mechanism is foundational. Every other repair process below depends on the cell having enough fuel to run it.
2. Triggering the Body's Nerve Growth Signals
Nerve repair is driven by a family of proteins that keep nerve cells alive, push them to regrow, and direct the rebuilding of the insulation around nerve fibers. Light therapy appears to shift the balance of these signals toward repair.
In a study published in the Journal of Neurotrauma, De Oliveira Martins et al. (2013) found that laser therapy at 904 nanometers raised levels of nerve growth factor in injured nerve tissue by 53% while lowering a second growth signal by 40%. That second signal, when elevated in an injured nerve, is associated with pain rather than with healing. The light pushed growth signaling toward repair and away from pain sensitization at the same time. Evidence tier: animal model.
A 2024 follow-up study by Martins et al. extended the finding. In a chronic nerve-compression model, light therapy at 904 nanometers reversed the suppressed growth signaling caused by the injury, raised nerve growth factor, increased the protein the body uses to build nerve insulation, and reduced a marker of ongoing nerve fiber damage. Evidence tier: animal model.
These growth signals matter because they govern myelin, the fatty sheath that wraps nerve fibers and lets electrical signals travel fast and cleanly. When myelin degrades (a feature of many neuropathies) transmission breaks down. Rebuilding it is central to getting function back.
3. Cooling Inflammation and Retraining the Immune Cells Around Damaged Nerves
Long-running inflammation keeps nerve damage going. Inflamed tissue presses on nerves, generates pain signals of its own, and creates a chemical environment in which repair simply cannot proceed. Red light therapy interrupts inflammatory signaling and lowers inflammatory messengers, breaking the cycle that holds damaged nerves in place.
Lim et al. (2013) traced how this happens at the level of the cell. Red light at 635 nanometers switched off a master inflammatory control system, the central switch that, once stuck in the "on" position, makes inflammation self-sustaining. Evidence tier: laboratory cell study.
There is a second, less obvious effect. The immune system's cleanup cells operate on a spectrum. At one end they are destructive and inflammatory; at the other they clear debris and actively support tissue repair. In chronic neuropathy these cells get stuck at the destructive end. A 2026 review by Ma et al. in Cellular and Molecular Neurobiology, drawing together laboratory and clinical evidence on light therapy for nerve pain, describes light therapy shifting those cells toward the repair state, quieting inflammatory signaling, and supporting nerve fiber regrowth. Evidence tier: narrative review of laboratory and clinical studies.
That shift has real downstream consequences. The repair-state immune cells clear away damaged material and recruit the cells responsible for rebuilding the nerve's protective sheath. A comprehensive 2025 review by Al Balah et al. in Lasers in Medical Science found that light therapy influences several immune cell populations at once, encouraging the regulatory cells that prevent the immune overreaction driving chronic nerve inflammation. Evidence tier: narrative review.
This changes the chemical conditions that were preventing repair from starting.
4. Rebuilding the Myelin Sheath
In many neuropathies the myelin sheath is damaged or stripped away. Myelin is made and maintained by Schwann cells (the cells that produce and repair nerve insulation), and light therapy appears to act on them directly.
Research shows that low-level laser therapy stimulates Schwann cells to multiply and to produce more nerve growth factor, supporting both the repair of existing myelin and the laying down of new insulation.
The clearest tissue-level evidence came from Chang et al. (2025). LED therapy at 807 nanometers increased Schwann cell growth, growth factor output, and myelin protein production in cell culture. In live animals with sciatic nerve injury, the same treatment significantly increased the thickness of the myelin sheath, the diameter of the nerve, and the diameter of the nerve fibers themselves. Evidence tier: cell culture and animal model.
Sen et al. (2025) confirmed the pattern in a crush-injury model. Both wavelength combinations tested outperformed placebo treatment on the number of nerve fibers and the area they occupied. Evidence tier: animal model. Mangueira et al. (2022) added a molecular layer of confirmation: using a light-scattering technique that identifies chemical composition directly in tissue, they found that laser-treated nerves had restored the specific fats and structural proteins that myelin and nerve architecture are built from. Untreated animals did not recover normal gait; treated animals did. Evidence tier: animal model.
5. Improving the Blood Supply to Nerve Tissue
Damaged nerves need oxygen and nutrients to heal, and in many neuropathies the delivery system is part of the problem. Near-infrared light raises production of a signaling molecule that widens blood vessels and increases flow into compromised tissue.
A randomized controlled trial by Gavish et al. (2020) captured this as it happened. Near-infrared light at 830 nanometers raised blood flow in the smallest vessels by 27% immediately, and the effect kept climbing to 54% over the twenty minutes after treatment ended. Evidence tier: randomized controlled trial in humans. The same study found the response varied between individuals depending on baseline skin temperature, a reminder that wavelength and body conditions both matter, and part of why devices delivering both red and near-infrared light are used in practice.
Beyond that immediate widening of existing vessels, light therapy stimulates the growth of new capillaries, improving the long-term supply of resources to damaged tissue while carrying waste away.
This matters most for people with diabetes. A 2026 study by Gavish et al. found that light therapy produced a sustained rise in wound-bed temperature in diabetic foot ulcers (an objective marker of improved blood flow) with the most compromised tissue showing the largest response. Evidence tier: clinical study. In diabetic nerve damage, poor circulation is both a cause and a consequence. Improving it addresses the supply problem that stalls healing even when the cell's repair machinery is otherwise intact.
6. Defending Against Oxidative Damage
Unstable oxygen molecules are a major driver of nerve damage, particularly in diabetes. In excess they attack nerve cell membranes, the cell's power plants, and its DNA, accelerating the breakdown of both nerve fibers and myelin.
Red light therapy restores the body's own antioxidant defenses in damaged tissue. In a diabetic neuropathy model, Abdel-Wahhab et al. (2018) showed light therapy lowering markers of oxidative damage and restoring the body's primary internal antioxidant more effectively than gabapentin did. Evidence tier: animal model. Karkada et al. (2022) confirmed the pattern in a diabetic nerve-damage wound model, finding that light at 655 and 808 nanometers reduced oxidative damage to cell membranes and raised protective enzyme activity, while tissue examination showed improved cell growth and repair. Evidence tier: animal model.
For nerve tissue already under chemical assault from high blood sugar, chemotherapy drugs, or chronic inflammation, this provides direct protection to the very cells responsible for repair.
7. Reducing Nerve Pain Through Three Non-Opioid Routes
Red light therapy lowers neuropathic pain through three separate pathways, none of which works the way pain medication works.
The first is anti-inflammatory. By lowering the inflammatory chemicals that switch on pain-sensing nerve fibers, light therapy reduces the chemical source of the signal. Tomazoni et al. (2021) demonstrated this in a randomized, triple-blinded, placebo-controlled trial: a single session of light therapy significantly reduced one of the primary molecules driving inflammatory pain, compared to placebo. Evidence tier: randomized controlled trial in humans.
The second is direct action on the nerve itself. Red and near-infrared light raises the threshold at which pain-sensing fibers will fire and slows the transmission of pain signals. Ma et al. (2026) describes a further dimension: light therapy helps stabilize the electrical excitability of the nerve membrane by restoring the cell's ion-balance machinery, directly reducing the hair-trigger state that characterizes nerve pain. Evidence tier: narrative review of laboratory and clinical evidence.
The third is the body's own pain-relief system. Serra and Ashmawi (2010), publishing in the Brazilian Journal of Anesthesiology, found that light therapy's pain relief was completely blocked by naloxone (a drug that shuts down the body's natural pain-relief receptors) while a serotonin-blocking drug had no effect on it at all. That control condition is what makes the finding precise: the relief runs through the body's own internal pain-relief pathway specifically, and not through a general sedative effect. Evidence tier: animal model. Cheng et al. (2021) reviewed all three pathways in The Journal of Pain and found support for each.
Together these explain why patients in clinical trials consistently report pain reduction, and why the effect tends to outlast the treatment session: the therapy is changing the biology that produces the pain, not intercepting the message.
What Clinical Trials Show About Red Light Therapy for Neuropathy
The evidence base for photobiomodulation in neuropathy now includes expert consensus statements, meta-analyses pooling thousands of patients, placebo-controlled crossover trials, and objective electrical measurements of nerve function. The findings hold up across different research teams, different countries, and different types of neuropathy.
Diabetic Peripheral Neuropathy
Diabetic neuropathy has the largest and most varied evidence base of any neuropathy type.
Ebadi and colleagues enrolled 60 patients in a 2023 randomized controlled trial and found that combined visible red (630 nm) and infrared (810 nm) light therapy significantly improved symptoms of diabetic neuropathy, both as patients reported them and as clinicians measured them, with no side effects recorded. Evidence tier: randomized controlled trial.
A 2023 systematic review by Anju et al. in Current Diabetes Reviews pooled eight studies and concluded that photobiomodulation is an effective, non-invasive and cost-efficient way to improve nerve pain and correct the abnormal foot pressure distribution that puts people at risk of ulcers. Evidence tier: systematic review.
In a trial of 200 patients with type 2 diabetes and peripheral neuropathy, Anju et al. (2025) found that the treatment group showed reduced neuropathic symptoms, improved protective sensation in the feet, better quality of life, and less pain. The study also recorded significant changes in two blood markers that track nerve cell health. Evidence tier: randomized controlled trial.
Objective electrical measurements strengthen the case well beyond what patients report. A 2024 trial by Javan Amoli et al. enrolled 45 patients with diabetic peripheral neuropathy and found that laser therapy alone significantly improved sensation in the soles of the feet and blood flow to the lower limbs as measured by a standard circulation test. Laser combined with a second physical therapy significantly improved how quickly electrical signals traveled through the main nerve in the lower leg, a direct measurement of nerve function rather than a questionnaire. The improvements were still present at three-month follow-up. Evidence tier: randomized controlled trial.
A three-arm comparison of 55 patients (Almasi et al., 2025) tested light therapy against low-frequency ultrasound and against control. The light therapy group showed the greatest improvement in quality-of-life scores. Evidence tier: randomized controlled trial.
The most recent evidence comes from a 2026 pilot trial by Santos et al., which treated 26 patients with diabetic neuropathy across 12 sessions over 23 days. Pain intensity fell significantly, with improvements also recorded in numbness, cramping, and dry skin. Evidence tier: randomized pilot trial.
Chemotherapy-Induced Peripheral Neuropathy
Chemotherapy-induced peripheral neuropathy is among the most disabling side effects of cancer treatment and among the hardest to address with drugs. It is also where the single strongest trial in the field sits.
The Argenta et al. (2017) trial enrolled 70 patients at the University of Minnesota in a randomized, double-blinded, placebo-controlled crossover design. Patients received light therapy or a placebo device three times weekly for six weeks, in 30-minute sessions. The results were unambiguous. Neuropathy scores in the treatment group fell 52.6% at eight weeks. The placebo group did not change at all. The difference was too large at every measurement point to be attributed to chance. Nearly 90% of treated patients reached clinically meaningful improvement. When patients who had been receiving the placebo crossed over to real treatment, they achieved the same results the original treatment group had, which rules out the possibility that the improvement was simply nerves recovering on their own over time. The benefit held regardless of how long a patient had lived with neuropathy or which chemotherapy drug had caused it. The trial's authors noted that these results compared favorably with duloxetine, the best available drug option, where roughly a third of patients report meaningful improvement. Evidence tier: randomized, double-blind, placebo-controlled crossover trial. The trial enrolled through a gynecologic oncology clinic, so the population was all women.
Some patients received light therapy combined with physiotherapy, and adding physiotherapy did not improve outcomes over light therapy alone. The light was doing the work.
A systematic review from MD Anderson Cancer Center (Hou et al., 2018) reviewed 35 studies covering 26 treatment options for this condition and rated photobiomodulation at "moderate benefit," the same evidence grade it assigned to duloxetine, which is the only drug the American Society of Clinical Oncology recommends for it. Evidence tier: systematic review.
More recent trials continue the pattern. A 44-patient placebo-controlled phase II trial (Teng et al., 2023) found significant improvements in the body's sense of limb position lasting up to 12 weeks. Evidence tier: randomized phase II trial. The NEUROLIGHT trial (Robijns et al., 2026), the most recently published trial in this area, enrolled 60 cancer patients and found significant improvement in mobility on a six-minute walking test along with significant pain reduction between groups. Evidence tier: randomized controlled trial.
Trigeminal Neuralgia and Facial Nerve Pain
Trigeminal neuralgia (severe, stabbing facial nerve pain) now has meta-analytic evidence behind it.
A meta-analysis of 9 randomized controlled trials covering 387 patients (Taddeucci et al., 2026) found that eight of the nine reported significantly greater pain reduction in the light therapy groups. The pooled analysis found a significant reduction in pain scores, with an average drop of just over two points on the pain scale. In most of the included trials, light therapy was added on top of existing medication rather than replacing it, and the authors concluded it works as an effective add-on with a favorable safety profile and the potential to reduce how much medication a patient needs. Evidence tier: systematic review and meta-analysis of randomized controlled trials.
The World Association for Photobiomodulation Therapy published a position paper in 2026 (Hanna et al.) establishing clinical practice guidelines for light therapy in facial and oral nerve pain. For burning mouth syndrome the evidence was rated Level I (the highest available) based on 204 patients across six randomized controlled trials at low risk of bias. Expert consensus recommendations were issued for trigeminal neuralgia and post-herpetic neuralgia. The paper confirmed light therapy as safe and effective for these conditions. Evidence tier: professional association clinical practice guideline.
Across 130 studies covering 6,879 patients, a 2026 systematic evidence map (Calabrò et al.) found that photobiomodulation produced the clearest short-term pain-relief signal of every intervention it evaluated for burning mouth syndrome. Evidence tier: systematic evidence map with meta-analysis.
For facial nerve conditions more broadly, Díaz et al. (2025) pooled 18 randomized controlled trials covering 1,220 patients with numbness, neuralgia, or facial paralysis. Light therapy significantly reduced pain scores (an average reduction of 3.5 points on a 10-point scale) and produced 45% faster recovery of sensation. Mild side effects occurred in fewer than 5% of cases. Evidence tier: systematic review and meta-analysis of randomized controlled trials.
Carpal Tunnel Syndrome
Carpal tunnel syndrome (compression of the median nerve at the wrist) represents a distinct mechanism of nerve damage, and it has been studied heavily.
A 2025 network meta-analysis by Chen et al. in Archives of Physical Medicine and Rehabilitation examined 49 randomized controlled trials enrolling 3,323 participants. Low-level laser therapy showed a significant benefit against control, with a large overall effect favoring light therapy. Evidence tier: network meta-analysis of randomized controlled trials.
A separate analysis of 13 randomized controlled trials (Lauxen et al., 2025) confirmed that light therapy significantly improved hand function, with the majority of included studies rated at low risk of bias. Evidence tier: systematic review and meta-analysis.
Compared to Medication
No human trial has yet compared light therapy head-to-head against gabapentin, pregabalin, or duloxetine. Two animal studies have tested the comparison directly. Abdel-Wahhab et al. (2018) ran a direct comparison in a diabetic rat model and concluded that low-level laser therapy was safer and more effective than gabapentin, producing larger reductions in inflammatory markers, oxidative damage, and liver enzymes. A follow-up from the same research team (Mannaa et al., 2021) reached the same conclusion, with light therapy outperforming gabapentin on markers gabapentin did not move at all. Evidence tier: animal model. These results point the way rather than settle the question, but they establish that the comparison rests on biology, not on hope.
Nerve Pain Generally
The most comprehensive recent review (Martins et al., 2025, Frontiers in Photonics) assessed the full body of evidence, laboratory, animal and clinical, and concluded that photobiomodulation is a biologically grounded and safe approach capable of addressing the multiple causes of nerve pain at once. It positioned locally applied light therapy as the most promising and clinically actionable option available. Evidence tier: comprehensive narrative review.
Across fibromyalgia, peripheral neuropathies, facial pain and musculoskeletal pain, a 2026 systematic review of randomized clinical trials (Ferreira et al.) found that most trials demonstrated significant pain reduction with light therapy, with a low rate of side effects. Evidence tier: systematic review of randomized controlled trials.
Diabetic Foot Ulcers: What Neuropathy Produces When Protective Sensation Is Gone
Diabetic foot ulcers are what happens when neuropathy removes protective feeling. Injuries go unnoticed, impaired healing turns them chronic, and chronic wounds can end in amputation. The evidence for light therapy here is unusually strong. A network meta-analysis of 99 randomized controlled trials and 7,356 patients (Hu et al., 2025) ranked low-level laser therapy first among all interventions compared on wound area reduction, outperforming both hyperbaric oxygen and topical oxygen therapy. A separate meta-analysis (Chen et al., 2025) found that light therapy made treated patients nearly five times more likely to achieve complete healing. And a double-blind, placebo-controlled home-use trial (Haze et al., 2022) found that at-home light therapy produced more than 90% wound closure in 7 of 10 frail elderly patients, against 1 of 10 in the placebo group. For the full picture on wound healing, see our dedicated article on red light therapy for wound healing.
The Structural Evidence: What Happens to the Nerve Itself
The question underneath every neuropathy treatment is whether it changes the tissue or only the sensation. The research answers this on two levels.
In the laboratory and in animals, the structural repair is visible and measurable. Chang et al. (2025) applied 807-nanometer LED light to sciatic nerve injury and documented thicker myelin sheaths, larger nerve diameter, and larger nerve fiber diameter under the microscope. Mangueira et al. (2022) used a chemical-fingerprinting technique to confirm that treated nerves had rebuilt the specific molecular components myelin is made of, while untreated animals failed to recover normal walking. Bayburt et al. (2025) found that light therapy improved the ratio between nerve fiber core and sheath thickness (the standard measure of well-formed myelin) with electrical testing confirming functional recovery alongside it. Evidence tier: animal models.
In humans, the measurable change is in how fast and how cleanly nerves conduct signals. In a 68-patient randomized, double-blind, placebo-controlled trial, Çelik et al. (2024) found that the light therapy group showed improvement in how quickly motor nerves carried signals and how fast they responded, at both 15-day and 3-month assessments. Sensory nerve speed also improved at 15 days. Every patient in both arms wore the same night splint, so the difference between groups is attributable to the light. Evidence tier: randomized, double-blind, placebo-controlled trial.
The same pattern appears in diabetic neuropathy. A 2024 randomized controlled trial by Javan Amoli et al. in 45 patients found significantly improved nerve conduction in the lower legs, with the gain still present at three-month follow-up. Evidence tier: randomized controlled trial.
Nerve conduction speed is an instrument reading, not a questionnaire. It does not respond to expectation. When it improves in a double-blind trial, something has changed in the nerve's ability to carry a signal.
What Has Not Been Tested
The evidence for red light therapy in neuropathy is substantial and still expanding. Several questions remain genuinely open, and they are worth knowing before you decide.
No human trial has compared light therapy head-to-head against gabapentin, pregabalin, or duloxetine. The indirect comparisons favor light therapy, and the animal head-to-head studies consistently favor it, but the definitive human comparison has not been run. Anyone telling you light therapy has been proven superior to these drugs in people is ahead of the evidence.
A comprehensive meta-analysis specifically for diabetic peripheral neuropathy is still in progress. A registered protocol (Fan et al., 2024; PROSPERO CRD42023466586) signals that pooled effect sizes for this population are coming, which will consolidate what is currently a set of individually positive trials into a single definitive estimate.
Long-term follow-up beyond about four months is thin. The Argenta trial showed improvement still present at 16 weeks (ten weeks after treatment ended) though somewhat reduced from its peak. That pattern suggests ongoing maintenance treatment supports sustained benefit, but the optimal long-term schedule has not been established.
None of these gaps contradicts the evidence that exists. They mark the edges of what has been studied, not problems with what has been found.
What an Effective Treatment Routine Looks Like
Nerves are among the slowest-healing tissue in the body. That single biological fact shapes everything about how this therapy needs to be used. Isolated sessions produce isolated results.
Daily, Consistent Light Therapy
Roughly 20 minutes daily is the pattern the research supports. Light therapy works by switching on cellular energy production, growth factor release, and tissue repair processes that need sustained activation across weeks and months. Skipping sessions interrupts the cascade. And because low to moderate light doses stimulate repair while excessive doses can suppress it, consistent daily application at sensible settings outperforms occasional high-intensity sessions (Huang et al., 2009).
Supporting the Conditions Nerves Need to Heal
Light provides the cellular signal. Nerves recovering from real damage also need raw materials and functional retraining.
A 2023 narrative review by da Silva et al., covering 14 studies on light therapy for diabetic nerve pain, concluded that the therapy showed the most promise specifically when combined with other approaches. A meta-analysis of 38 studies on upper-limb neuropathies (Bula-Oyola et al., 2021) found that combined approaches outperformed single interventions. And the Martins et al. (2024) animal study found that light therapy combined with B-complex vitamins produced greater increases in nerve growth and myelin-building proteins than either alone.
Nerve-support nutrition. The evidence is strongest for alpha-lipoic acid: the SYDNEY 2 trial (Ziegler et al., 2006, Diabetes Care, n=181) found that 600 mg daily produced statistically significant symptom improvement against placebo. Acetyl-L-carnitine has structural evidence behind it: Sima et al. (2005, Diabetes Care, n=1,257 across two pooled trials) demonstrated significant increases in nerve fiber numbers and in clusters of regenerating fibers taken from nerve biopsies, which is direct evidence of regrowth in humans rather than symptom relief. Benfotiamine, a form of vitamin B1, showed improvement in the BENDIP trial (Stracke et al., 2008, n=165) at 600 mg daily, though the evidence there is lighter than for the first two.
A safety point on vitamin B6. Vitamin B6 at high doses can itself cause peripheral neuropathy. The US Tolerable Upper Intake Level is 100 mg per day, and in 2023 the European Food Safety Authority revised its own limit down to 12 mg per day specifically because of nerve damage risk. B6 supplementation should correct a confirmed deficiency, not serve as high-dose therapy. If you are taking B vitamins for neuropathy, discuss the dose with your physician.
Targeted movement. Nerves are communication pathways. Even when the fiber itself heals, the pathways for balance, coordination and sensation do not come back on their own. They have to be challenged and retrained through specific movement.
Reducing dietary inflammation. Heavily processed food drives body-wide inflammation that compounds nerve damage. Cleaning up what you eat does not heal nerves directly, but it stops actively working against the repair the light therapy is trying to start.
Conclusion
Peripheral neuropathy is damage to nerve tissue, and repairing damaged tissue requires something that acts at the level of the cell. Medication manages the pain signal. Red light therapy acts on the seven biological processes that determine whether nerve tissue heals: energy production, growth factor signaling, inflammation and immune cell behavior, myelin rebuilding, blood supply, oxidative defense, and pain modulation through pathways that have nothing to do with opioid prescriptions.
The clinical evidence now includes a 21-expert international consensus, published in a leading medical journal, stating plainly that photobiomodulation is effective for peripheral neuropathy. It includes the largest placebo-controlled trial in chemotherapy-induced neuropathy, where nearly 90% of treated patients reached meaningful improvement while the placebo group did not change. It includes meta-analytic evidence across trigeminal neuralgia, carpal tunnel syndrome, facial nerve conditions and diabetic foot ulcers, covering thousands of patients. It includes objective electrical measurements of improved nerve conduction in double-blind human trials. And it includes detailed laboratory and animal evidence showing the tissue-level repair (thicker myelin, larger nerve fibers, restored nerve architecture) that explains why those human results happen.
The safety record is excellent, the biological rationale is clear, and the institutional recognition is arriving. If your current treatment plan stops at managing symptoms, this is the information you need in order to have a real conversation about what else is possible, and to decide, for yourself, what you want to try next.
